In March 2016, California citizen Kristi Lauris registered the first wrongful fatality Tasigna lawsuit resistant to the drug’s company, Novartis AG. Her dad, Dainis Lauris, perished in 2014 from an enormous stroke after moving over from Gleevec to Tasigna (universal name: nilotinib).
With medical studies demonstrating a link between Tasigna and atherosclerosis-related accidental injuries (including sudden loss of life), more statements will definitely follow. For more information about Tasigna Lawsuit or Tasigna Atherosclerosis Lawsuit, you can browse online.
Tasigna is a second-generation tyrosine kinase inhibitor (TKI) medication that’s approved to Philadelphia-positive chronic myeloid leukemia (Ph+ CML) patients. Swiss medication maker Novartis developed Tasigna to displace its first-generation TKI medication, Gleevec (imatinib), from then on patent expired in 2015.
And it’s really evident why Novartis sought another patented cancer tumor drug to displace Gleevec: in 2015 exclusively, it made $4.7 billion in global sales. Over fifty percent those profits came up immediately from leukemia patients in America.
In 2017, 28 Tasigna pills costs $12,104.20 at WalMart. Now, Novartis is operating two large Tasigna professional medical tests on Parkinson’s and Alzheimer’s patients, expecting to increase its FDA agreement.
Japanese Tasigna Clinical Trial SUFFERING FROM Legal Woes
Novartis encountered misconduct charges related to Tasigna’s 2013 Japanese specialized medical trials assessing different leukemia medicine results in 3,000 research subjects. Japanese representatives opened a study after attorneys learned Novartis didn’t include 33 undesirable event information from that specialized medical trial.